|1.||Pilc, A: 4 articles (09/2015 - 01/2000)|
|2.||Danysz, Wojciech: 3 articles (11/2009 - 09/2005)|
|3.||Schoepp, Darryle D: 3 articles (06/2008 - 08/2006)|
|4.||Monn, James A: 2 articles (11/2014 - 04/2007)|
|5.||Morè, Lorenzo: 2 articles (11/2009 - 02/2009)|
|6.||Pietraszek, Małgorzata: 2 articles (11/2009 - 02/2009)|
|7.||Schlumberger, Chantal: 2 articles (11/2009 - 02/2009)|
|8.||Ossowska, K: 2 articles (01/2000 - 01/2000)|
|9.||Wolfarth, S: 2 articles (01/2000 - 01/2000)|
|10.||Grygier, B: 1 article (09/2015)|
|1.||Schizophrenia (Dementia Praecox)
02/01/2009 - "In conclusion, LY354740 was effective in models for anxiety and positive symptoms of schizophrenia but not in models for sensorimotor gating and cognitive impairment."
01/01/2011 - "Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclinical animal models of anxiety and schizophrenia. "
02/01/2009 - "The aim of this study was to evaluate further the effect of the mGluR2/3 agonist, LY354740 [(+)-2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylate monohydrate] in animal models relevant to both psychotic and cognitive impairment in schizophrenia. "
11/01/2014 - "These data strengthen the validity of PRS mice as a model of schizophrenia, and show for the first time a pharmacodynamic difference between LY379268 and LY354740 which might be taken into account in an attempt to explain the differential effect of the two drugs across mouse models. "
11/25/2009 - "In conclusion, in selected rodent models for positive schizophrenia symptoms, ADX47273 showed better efficacy than LY354740."
01/01/1999 - "LY354740 and LY379268 were protective against transient global ischemia in gerbils when dosed intraperitoneally. "
01/01/2015 - "In the present study, reduced mechanical thresholds for hindpaw-withdrawal reflex were found in mice after transient hindpaw ischemia, which was produced by a high pressure applied around the hindpaw for 30 min. The reduction in the threshold was blocked by spinal application of LY354740, a specific agonist of group II metabotropic glutamate receptors. "
|3.||Anxiety Disorders (Anxiety Disorder)
08/01/2006 - "LY354740 is a potent and selective mGlu2/3 receptor agonist with activity in models of psychiatric disorders (anxiety, psychosis), and early clinical studies in anxiety patients. "
06/01/2008 - "LY354740, a potent and selective mGlu (metabotropic glutamate receptor)2/3 agonist, has shown efficacy in the treatment of generalized anxiety disorder (GAD). "
09/01/2005 - "Eli Lilly and Co is developing LY-544344, a prodrug of the metabotropic glutamate receptor 2/3 agonist LY-354740, for the potential treatment of anxiety disorders."
|4.||Panic Disorder (Panic Attack)
11/01/2005 - "We present the results obtained with LY354740, in a placebo-controlled double-blind randomized study with paroxetine as an active comperator in outpatients with panic disorder. "
11/01/2005 - "Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740."
04/27/2000 - "LY354740 treatment was equally efficacious as alprazolam in preventing lactate-induced panic attacks in this model. "
03/01/2000 - "Our data suggest that the group II mGluR agonist LY354740 possesses anti-seizure activity and may modify the effects of some conventional antiepileptic drugs."
11/01/1999 - "In the present experiments, the selective group II mGluR agonist (+)-2-aminobicyclo-[3.1.0]hexane-2,6-dicarboxylic acid (LY 354740) at doses from 4 to 16 mg/kg) administered prior to the injection of pentetrazole (80 mg/kg) or picrotoxin (3.2 mg/kg) produced a dose-dependent decrease in the number of mice exhibiting clonic convulsions. "
03/01/2000 - "LY354740 (4-16 mg/kg) administered prior to an injection of pentylenetetrazol (80 mg/kg) or picrotoxin (3.2 mg/kg) produced a dose-dependent decrease in the number of mice exhibiting clonic convulsions, but had no effect on N-methyl-D-aspartate (NMDA, 150 mg/kg)-induced convulsions. "
11/01/1999 - "Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures."
03/01/2000 - "LY354740 potentiated the anticonvulsant activity of the conventional antiepileptic drug diazepam, significantly decreasing the ED50 for that drug's effect on pentylenetetrazol-induced convulsions by 30%, but had no influence on anticonvulsant activity of ethosuximide and valproic acid. "
|2.||Glutamic Acid (Glutamate)
|3.||Asp(5)- oxytocin (OXA)
|4.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|5.||metabotropic glutamate receptor 2
|7.||Antipsychotic Agents (Antipsychotics)
|8.||S- (4- fluorophenyl)- (3- (3- (4- fluorophenyl)- (1,2,4)- oxadiazol- 5- yl)piperidin- 1- yl)methanone
|10.||Dizocilpine Maleate (Dizocilpine)